Portfolio company Carmot Therapeutics entered a definitive merger agreement to be acquired by Roche for $2.7B upfront plus up to $400M in milestones.
Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes
Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes. They utilize Chemotype Evolution, a pioneering drug discovery platform, to identify novel incretin receptor signaling targets.